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Background: Lysophosphatidic acid (LPA) is a signalling phospholipid with multiple biological functions, mainly
mediated through specific G protein-coupled receptors. Aberrant LPA signalling is being increasingly implicated in
the pathology of common human diseases, such as arteriosclerosis and cancer. The lifetime of the signalling pool
of LPA is controlled by the equilibrium between synthesizing and degradative enzymatic activity. In the current
study, we have characterized these enzymatic pathways in rat brain by pharmacologically manipulating the
enzymatic machinery required for LPA degradation.
Results: In rat brain cryosections, the lifetime of bioactive LPA was found to be controlled by Mg2+-independent,
N-ethylmaleimide-insensitive phosphatase activity, attributed to lipid phosphate phosphatases (LPPs).
Pharmacological inhibition of this LPP activity amplified LPA1 receptor signalling, as revealed using functional
autoradiography. Although two LPP inhibitors, sodium orthovanadate and propranolol, locally amplified receptor
responses, they did not affect global brain LPA phosphatase activity (also attributed to Mg2+-independent, N-
ethylmaleimide-insensitive phosphatases), as confirmed by Pi determination and by LC/MS/MS. Interestingly, the
phosphate analog, aluminium fluoride (AlFx
- ) not only irreversibly inhibited LPP activity thereby potentiating LPA1
receptor responses, but also totally prevented LPA degradation, however this latter effect was not essential in order
to observe AlFx
- -dependent potentiation of receptor signalling.
Conclusions: We conclude that vanadate- and propranolol-sensitive LPP activity locally guards the signalling pool
of LPA whereas the majority of brain LPA phosphatase activity is attributed to LPP-like enzymatic activity which,
like LPP activity, is sensitive to AlFx
- but resistant to the LPP inhibitors, vanadate and propranolol.Background
Lysophosphatidic acid (LPA, 1- or 2-acyl-sn-glycero-3-
phosphate) is a signalling phospholipid mediating mul-
tiple biological responses, such as cellular proliferation,
prevention of apoptosis, and platelet aggregation, and
is involved in the development and function of the ner-
vous, cardiovascular, immune, and reproductive systems
[1,2]. Aberrant LPA signalling has been claimed to be
associated with the pathology of common human diseases,
such as arteriosclerosis [3] and cancer [4]. Signalling by* Correspondence: Niina.Aaltonen@uef.fi
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reproduction in any medium, provided the orLPA is mainly mediated through specific G protein-
coupled receptors (GPCRs) [5-7]. The receptors for LPA
are widely expressed, being found in the brain, circula-
tion and digestive tract. Currently, there are five GPCRs
that have been identified as bona fide receptors for LPA
(LPA1-5) along with a putative sixth receptor (LPA6) [8].
Physiologically relevant levels of LPA can be found in
serum and other body fluids. In addition, several cell
types, including platelets, adipocytes, and ovarian cancer
cells, can produce and release LPA. Significant amounts
of LPA have been detected from brain tissue [9-11]. It is
postulated that the majority of bioactive LPA is gener-
ated extracellularly from lysophospholipids, such as lyso-
phosphatidylcholine (LPC), by the plasma ecto-enzyme,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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motility factor originally isolated from the conditioned
medium of cancer cells [12]. Intracellularly, LPA can be
generated by phospholipase A1/A2 (PLA1/PLA2, respect-
ively) -catalyzed deacylation of phosphatidic acid (PA)
[13,14]. Other proposed pathways for LPA generation
include de novo biosynthesis either from glycerol-3-
phosphate (GP) by glycerol-3-phosphate acyltransferase
or from monoacylglycerol (MAG) by monoacylglycerol
kinase [15].
After being produced, the lifetime of the signalling
pool of LPA is thought to be controlled by enzymatic
degradation. LPA is rapidly dephosphorylated by a family
of integral membrane proteins known as lipid phosphate
phosphatases (LPPs) [16-18]. The LPP family (also
known as PAP2) comprises four members (LPP1, LPP2,
LPP3 and a splice variant LPP1a) which dephosphorylate
their lipid substrates, namely LPA, PA, sphingosine 1-
phosphate (S1P), and ceramide 1-phosphate [19-21]. All
the LPP subtypes are expressed in the brain [18,19,22]
but very little is known about their functional roles.
A hallmark of LPP activity is that it does not require
Mg2+ and is resistant to the alkylating agent, N-
ethylmaleimide (NEM) [23]. The other known pathways
for LPA metabolism include de novo formation of PA by
lysophosphatidic acid acyltransferase and lysophospholi-
pase -catalyzed hydrolysis of the acyl group to form gly-
cerophosphate [15]. The two degradative pathways
generating inorganic phosphate (Pi) as a result of LPA
degradation are depicted in Figure 1.
[35 S]GTPγS autoradiography represents a powerful















Figure 1 The two enzymatic pathways generating inorganic phospha
pathway, lipid phosphate phosphatases (LPPs) dephosphorylate LPA resulti
(MAG) and Pi. MAG is further hydrolyzed by monoglyceride lipase (MGL), re
glycerol (G). In the LPA! GP! G pathway, lysophospholipases (LPLs) cat
glycerophosphate (GP). GP can be further metabolized by GP phosphatasedependent Gi/o protein activity directly in brain cryosec-
tions (for reviews, see [24,25]). In addition to a
receptor’s anatomical distribution, [35 S]GTPγS auto-
radiography can monitor the receptor-G protein axis in
its native cellular microenvironment and is therefore
often referred to as functional autoradiography. Our
previous studies have demonstrated that brain sections
retain the capacity to generate endogenous GPCR ago-
nists, such as adenosine and LPA, during incubation.
This results in tonic adenosine A1 and LPA receptor ac-
tivity in anatomically defined brain regions and there-
fore serves as a convenient functional readout to
monitor agonist activity at the two receptors [26-28].
The LPA-evoked [35 S]GTPγS binding response in rat
brain sections reflects LPA1 receptor activity, as it is
sensitive to the LPA1/3-selective antagonist Ki16425 and
is restricted to the developing white matter tracts
[24,26,29]. This labelling pattern faithfully mirrors the
known expression pattern of LPA1 receptors in the
developing rat brain [30-33].
Our previous studies indicated that the enzymatic
machinery generating and metabolizing membrane-
derived lipid mediators was well preserved in brain cryo-
sections. We recently demonstrated that a comprehensive
elimination of the enzymatic hydrolysis of the endocanna-
binoid 2-arachidonoylglycerol (2-AG) in brain sections
leads to 2-AG accumulation and subsequent cannabinoid
CB1 receptor activation, as successfully revealed using
functional autoradiography [34]. Using this approach, we
show here that pharmacological inhibition of LPP activity
in brain sections with vanadate or propranolol results
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ng in the generation of equimolar amounts of monoacylglycerol
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alyze the deacylation of LPA with the concomitant formation of
(GPase) activity thereby generating equimolar amounts of Pi and G.
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brain level, also attributable to Mg2+ -independent, NEM-
resistant LPP-like phosphatases. We show further that the
phosphate analog AlFx
- not only potentiates LPA1 receptor
signalling, but also totally prevents LPA degradation,
resulting in the accumulation of several LPA species in
brain sections, as demonstrated by LC/MS/MS measure-
ments. The presently described approach offers a versatile
tool to monitor the strength of lipid-GPCR signalling axis
in anatomically defined brain structures and may prove
useful also for further studies exploring enzymatic path-
ways estimating the lifetime of still uncharacterized
endogenous signalling lipids.
Results
The LPP inhibitors Na3VO4 and propranolol locally
amplify LPA1 receptor signalling without affecting global
LPA degradation
The LPP-mediated degradation of LPA is susceptible to
the phosphatase inhibitor sodium orthovanadate
(Na3VO4) [35] and to propranolol [20,36], better known
as a classical β-adrenoceptor blocking agent e.g. used in
the treatment of hypertension. Another β-blocker, nado-
lol, has no demonstrable LPP inhibiting capacity [36]
and therefore can serve as a useful control compound.
We tested the effects of these compounds on basal LPA1
receptor signalling. Treatment of brain sections with
propranolol (1 mM) or Na3VO4 (100 μM) resulted in sti-
mulated [35 S]GTPγS binding responses that were
restricted to the white matter areas of 4 week-old rat
brain (Figure 2a). The observed labelling pattern was
fully reproduced by the addition of exogenous LPA
(50 μM) and all the evoked responses, including the
tonic LPA1 receptor activity observed under basal condi-
tions, were abolished by treatment with the LPA1/3
receptor selective antagonist Ki16425 (5 μM) (Figure 2a
and b). Previously, we demonstrated that Ki16425 dose-
dependently diminished the basal and LPA-evoked [35 S]
GTPγS binding responses in the white matter tracts
(IC50 values 35 ± 9 nM and 87 ± 19 nM, respect-
ively) [28]. Dose–response studies revealed that the
maximal effective concentrations for Na3VO4 and pro-
pranolol were 100 μM and 1 mM, respectively (See
Additional file 1: The maximal effective concentrations
for Na3VO4 and propranolol). As expected, treatment
with nadolol (1 mM) had no effect on basal LPA1 re-
ceptor signalling (Figure 2c, Additional file 2: Propran-
olol, but not nadolol, induces LPA mimicking binding
response). Both Na3VO4 and propranolol, but not
nadolol, amplified the LPA-evoked (0.5 μM to 50 μM)
binding responses (Figure 2c). To rule out the direct
agonism of propranolol and vanadate at the LPA1 re-
ceptor, we performed classical filtration-based [35 S]
GTPγS binding assay and found that neither compoundwas able to stimulate [35 S]GTPγS binding to the rat
cerebellar membranes, whereas exogenous LPA evoked a
dose-dependent response (See Additional file 3: Propran-
olol and vanadate do not activate LPA1 receptors). We
additionally observed that the LPA3 receptor-preferring
agonist (2 S)-OMPT (0.5 μM to 50 μM) induced only a
weak response in the brain of a 4-week old rat when
compared to signal achieved with exogenous LPA
(10 μM) (See Additional file 4: Comparison of the [35 S]
GTPγS binding responses between LPA and (2 S)-
OMPT). This lends further support to the argument that
observed LPA-evoked signalling is reflecting the activity
of the myelin enriched LPA1 receptors instead of LPA3
receptors that are expressed to a lesser degree in the
brain [5]. Finally, we found that exogenously added auto-
taxin substrate LPC did not boost tonic LPA1 receptor
activity suggesting that tonic LPA1 activity in brain sec-
tions is not due to LPA formed as a result of autotaxin
activity (See Additional file 5: Autotaxin is not respon-
sible for tonic LPA1 activity).
The LPPs catalyze the hydrolysis of the phosphate
group of their lipid substrates resulting in the generation
of inorganic phosphate (Pi). The measurement of the
released Pi offers a straightforward way to monitor LPP
activity [37]. In preliminary experiments, incubation of
brain sections with exogenously added LPA, PA and S1P
resulted in Pi formation, indicating that lysophospholipid-
degrading phosphatases were active under the assay
conditions employed (See Additional file 6: Phosphate
generation from exogenous LPA, PA, and S1P). To con-
firm that Pi generation was dependent on brain tissue,
empty slides were incubated under identical conditions
but in this case, there was no generation of Pi from LPA
(data not shown). Further studies with LPA (50 μM) indi-
cated, that LPP-like phosphatase activity accounted for the
majority of LPA degradation, as ~ 93% of LPA-derived Pi
was formed as a result of Mg2+-independent, NEM-
resistant phosphatase activity (Figure 3). In the routine
assay buffer containing Mg2+, 46 ± 1% (mean±SEM, n= 3)
of exogenous LPA (50 μM, corresponding to 47.5 nmol
potentially available Pi per slide) was degraded during the
90 min incubation whereas in the Mg2+-free assay buffer
supplemented with NEM (5 mM), the respective figure
was 44± 3%. However, neither the LPP inhibitors Na3VO4
(100 μM), propranolol (1 mM), nor nadolol (1 mM)
affected total LPA phosphatase activity in a statistically
significant manner, assessed at the bulk level of brain sec-
tions (Figure 3). In line with this, when the LPA content of
brain sections treated with Na3VO4 or propranolol was
analyzed using LC/MS/MS, there was no significant accu-
mulation of LPA when compared to control sections that
were incubated in the absence of these inhibitors (data
not shown). We undertook a search for additional inhi-




Figure 2 Vanadate and propranolol evoke LPA-mimicking [35 S]
GTPγS binding response that is sensitive to LPA1/3 receptor
antagonist. (a) Coronal brain sections were incubated using a
three-step autoradiography protocol as detailed in Methods. Test
chemicals were included during the [35 S]GTPγS labelling step (step
3) in the presence of 0.1% BSA. Treatment with propranolol (1 mM)
or Na3VO4 (100 μM), results in G protein activity in the LPA1 receptor
enriched white matter tracts, a response that is mimicked by
exogenous LPA (50 μM). The LPA1/3 receptor antagonist Ki16425
(5 μM) abolishes all the evoked responses in the white matter
regions, including the tonic LPA1 signal observed under basal
conditions (cc, corpus callosum). Scale bar = 2 mm. The eight-point
[14 C] standard used in the quantification is shown at the bottom of
image. (b) and (c) Quantitative data of the binding responses
including the dose response for exogenous LPA (0.5 μM to 50 μM)
with or without the simultaneous treatment with the inhibitors.
Autoradiography films were digitized and [35 S]GTPγS binding was
quantified from the corpus callosum of coronal sections of 4 week-
old rat brain, as described in Methods. Quantitative data are
calculated as nCi/g equivalents with non-specific binding subtracted
from total binding. The data are expressed as a percentage of basal
binding (mean+ SEM) from six individual animals (n = 6). Significance
level: (b) ***p< 0.001 compared to the treatment without Ki16425
(c) ***p< 0.001 compared to control in each LPA concentration.
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tases in brain sections.
The phosphate analog aluminium fluoride amplifies LPA1
receptor signalling and totally prevents LPA degradation
resulting in bulk accumulation of endogenous LPA species
Sodium fluoride (NaF) is commonly used as a phos-
phatase inhibitor. Aluminium fluoride (AlFx
-) acts as atransition stage phosphate analog also capable of inhi-
biting several phosphatases [38]. AlFx
- forms spontan-
eously in aqueous solutions in the presence of aluminium
(Al3+) and fluoride ions. We pretreated brain sections
with NaF or AlFx
- in order to test whether these com-
pounds could affect LPA receptor activity and/or LPA
degradation. Interestingly, when sections were pretreated
with AlFx
- (AlCl3 50 μM+NaF 10 mM), a stimulated
[35 S]GTPγS binding response throughout the LPA1
receptor-enriched white matter regions was evident
(Figure 4a and b). This labelling pattern was fully mim-
icked by the addition of exogenous LPA (0.5 μM to
50 μM) (Figure 4a and b), and was blocked by Ki16425
(5 μM) (Figure 4a and c). Similarly, pretreatment of brain
sections with NaF (10 mM) resulted in stimulated [35 S]
GTPγS binding responses throughout the white matter
regions (Figure 4a). Pretreatment with these compounds
was sufficient to evoke LPA1 receptor signalling, suggest-
ing that in contrast to the reversibly acting inhibitors
Na3VO4 and propranolol (that needed to be present dur-
ing the [35 S]GTPγS labelling step), AlFx
- and NaF had
inhibited LPP activity in an irreversible manner.
We wished to explore in more detail the mode of in-
hibition of these compounds, as well as the behaviour of
NaF in our experimental setting. This was justified by
the fact that aluminium is a common constituent of
glassware and F- can etch it from the glass. Deforoxa-
mine mesylate (DFOM) is an aluminium and iron(III)
chelator that can be used in experimental settings to
reveal if aluminium is present in the system. When
brain sections were treated with DFOM (50 μM), the
responses to AlFx
- and NaF (10 mM) in functional
Figure 3 Brain tissue dephosphorylates LPA through LPP-like
phosphatases that are resistant to propranolol and Na3VO4.
Slides with three horizontal rat brain sections underwent the
autoradiography mimicking incubation protocol, as detailed in
Methods (a), or were pretreated with NEM (5 mM) followed by the
autoradiography mimicking protocol with the exception that Mg2+
was omitted from the incubation buffer (b). Following 90 min
incubation in the presence of 0.1% BSA together with the indicated
combinations and concentrations of the compounds, the assay
buffer was quantitatively collected and the Pi content was
determined as described in Methods. Note that the bulk of LPA
degradation is due to NEM resistant and Mg2+ independent
phosphatase activity (compare a and b) and that Na3VO4 (100 μM),
propranolol (1 mM) or nadolol (1 mM) do not affect basal or
LPA-derived Pi generation in a statistically significant manner. The
data are expressed as nmol Pi generated per slide (mean+ SEM) and
were obtained from three independent experiments performed in
triplicate (n = 3). Significance level: Bars indicated with ¤ represent
significant difference (p< 0.001) to bars indicated with # but there
is no significant difference between the bars marked with the
same symbol.
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noteworthy that DFOM needed to be added together
with AlFx
- or NaF in order to achieve this reversal; if
added after pretreatment with AlFx
- or NaF, DFOM was
ineffective (data not shown). These studies indicate that
AlFx
- acted as an irreversible inhibitor of brain LPP activ-
ity thereby amplifying tonic LPA1 receptor activity. The
general phosphatase inhibitor, NaF per se, did not inhibitLPPs, but mimicked the action of AlFx
- based on the abil-
ity of F- to etch Al3+ from the glass slides.
We were curious to examine whether AlFx
- could also
inhibit LPA degradation at the bulk brain level. When
sections were pretreated with AlFx
- but then omitted
from all subsequent steps, AlFx
- readily facilitated LPA1
receptor signalling (Figure 4, Figure 5a), but such a pre-
treatment did not inhibit LPA degradation in a statisti-
cally significant manner. Degradation of exogenous LPA
(50 μM) alone yielded 22.6 ± 1.2 nmol Pi per slide
whereas pretreatment with AlFx
- followed by incubation
with exogenous LPA yielded 21.4 ± 0.4 nmol Pi per slide
(mean ± SEM, n = 3). However, when added together
with LPA, AlFx
- totally (and NaF partially) blocked the
formation of LPA-derived Pi, thus providing evidence of
the ability of these compounds to inhibit the vanadate-
and propranolol-insensitive pool of LPA phosphatases in
a reversible manner (Figure 5b). Treatment with DFOM
(50 μM) totally prevented the ability of AlFx
- and NaF to
inhibit the degradation of LPA (Figure 5b), indicating
that AlFx
- , rather than NaF, was the active compound.
To further explore the consequences of total inhibition
of LPA phosphatase activity, AlFx
- -treated brain sections
were incubated for 40 min in autoradiography buffer, the
buffer was removed and tissue LPA content extracted
using chloroform-methanol, followed by LC/MS/MS
analysis. Four LPA species with different acyl substitu-
tions (16:0 LPA, 18:1 LPA, 18:0 LPA and 20:4 LPA)
were examined in the present study. The relative abun-
dances of the four LPA species in brain sections
incubated under control conditions were 20:4 LPA 
16:0 LPA< 18:1 LPA< 18:0 LPA. The amounts of three
of these species (16:0 LPA, 18:1 LPA and 20:4 LPA) were
significantly increased after AlFx
- treatment when com-
pared to control sections (Figure 6). These experiments
indicate that total blockade of LPA phosphatase activity
with AlFx
- treatment resulted in accumulation of several
endogenous LPA species at the bulk brain level. However,
no such bulk LPA accumulation was required to observe
the AlFx
- -evoked potentiation of LPA1 receptor signalling.
The LPA!MAG!G pathway efficiently degrades
exogenous LPA whereas the LPA!GP!G pathway
is inactive
In addition to the LPA!MAG!G pathway (Figure 1),
another Pi generating pathway for LPA degradation
involves its deacylation to form glycerophosphate which
is further dephosphorylated by glycerophosphatases to
glycerol (the LPA!GP!G pathway) (Figure 1). Since
there are two degradative pathways for LPA that poten-
tially release Pi, we wished to clarify which pathway
accounts for LPA degradation in our model. Rat cerebel-
lar membranes have been extensively used in our labora-
tory to study degradation of labile lipid messengers such
Figure 4 AlFx
- and NaF evoke LPA-mimicking [35 S]GTPγS binding response that is sensitive to LPA1/3 receptor antagonist. (a) Horizontal
brain sections were incubated using a three-step autoradiography protocol as described in Methods. AlFx
- (NaF 10 mM+AlCl3 50 μM) was
included during the 40 min preincubation step (step 1), NaF (10 mM) was included in step 2, and LPA (50 μM) in step 3, whereas Ki16425 (5 μM)
was present throughout all steps. The buffer in all the steps additionally contained 0.1% BSA. Treatment with AlFx
- and NaF results in region-
specific G protein activity that is restricted to the LPA1 receptor enriched white matter tracts, a response that is mimicked by exogenous LPA and
is sensitive to Ki16425 (cc, corpus callosum; fi, fimbria of the hippocampus). Scale bar = 5 mm. (b) and (c) Quantitative data of the binding
responses. Autoradiography films were digitized and [35 S]GTPγS binding was quantified from corpus callosum of the coronal sections of 4 week-
old rat brain, as detailed in Methods. Data are calculated as nCi/g equivalents with non-specific binding subtracted from the total and are
expressed as a percentage of basal binding (mean+ SEM) from six individual animals (n = 6). Significance level: (b) ***p< 0.001 compared to
control in each LPA concentration (c) ***p< 0.001 compared to the treatment without Ki16425.
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known to be present in the cerebellum [30] we performed
kinetic monitoring of Pi production from exogenous LPA
and glycerol 3-phosphate (GP) after incubation with rat
cerebellar membranes in 96-well-format. In this setting,
cerebellar membranes generated Pi from LPA (10 μM) but
there was no Pi generation from GP (10 μM) (Figure 7a),
indicating that the Pi formed from LPA in our experimen-
tal setting is principally due to LPP/LPP-like activity. As
a further proof, we used the dephosphorylation-resistant
thio-analog of LPA, (2 S)-OMPT, that is also the LPA3
receptor.-preferring agonist. As expected, there was no Pi
generation from (2 S)-OMPT (10 μM) (Figure 7a).
Since both of the two Pi releasing pathways for LPA
degradation finally produce glycerol, we assessed cere-
bellar membrane-dependent glycerol generation from
exogenous LPA in brain tissue. Monoglyceride lipase
(MGL) is believed to be mainly responsible for the
MAG!G conversion. In addition, two novel α/β-hydrolase
domain containing proteins, ABHD6 and ABHD12, havebeen identified to hydrolyze brain endocannabinoid 2-
arachidonoylglycerol (2-AG) [40] and together the three
serine hydrolases account for ~99% of brain 2-AG
hydrolase activity [41]. It is therefore likely that in
addition to MGL, ABHD6 and ABHD12 are involved in
the degradation of both 1- and 2-monoacylglycerols. To
delineate the relative contributions of the three hydro-
lases, we pretreated cerebellar membranes with two
serine hydrolase inhibitors, methylarachidonoylfluoro-
phosphonate (MAFP) and compound JZL184. The
former is a potent, non-selective inhibitor of MGL
[39,42] that also inhibits ABHD6/ABHD12, whereas the
latter is a MGL-selective inhibitor [43]. As expected, in
rat cerebellar membranes incubated together with LPA
(10 μM), glycerol production closely matches with Pi
generation (Figure 7a and b), indicating that MAG!G
conversion takes place under the assay conditions
employed. With MAFP pretreatment (1 μM), LPA-derived
glycerol production was decreased by 91% (Figure 7b).
With JZL184 pretreatment (100 μM), the corresponding
Figure 5 AlFx
- (not NaF) generates the LPA1 receptor-mediated response; AlFx
- also blocks the LPA phosphatase activity. (a) Functional
autoradiography using horizontal brain sections was performed using a three-step protocol as detailed in Methods. AlFx
- (NaF 10 mM+AlCl3
50 μM) was included during the 40 min pre-incubation step (step 1), NaF (10 mM) was present in step 2 whereas deferoxamine mesylate (DFOM,
50 μM) was present throughout steps 1–3 and in addition during a 10 min pre-incubation prior to AlFx
- treatment. The buffer in step 3
additionally contained 0.1% BSA. Both NaF and AlFx
- induce [35 S]GTPγS binding in the LPA1 receptor enriched white matter areas. The responses
to AlFx
- and NaF are totally abolished with the aluminium and iron(III) chelator DFOM (cc, corpus callosum; fi, fimbria of the hippocampus). Scale
bar = 5 mm. (b) Slides with two horizontal brain sections underwent the three-step autoradiography mimicking protocol as detailed in Methods.
AlFx
- (NaF 10 mM+AlCl3 50 μM) and NaF (10 mM) were present during the 90 min incubation step (step 3). DFOM (50 μM) was present in steps 2
and 3. The buffer in step 3 additionally contained 0.1% BSA. After the final incubation step, the assay buffer was quantitatively collected and the
Pi content was determined as described in Methods. Note that NaF partially and AlFx
- totally inhibit LPA-derived Pi formation and that DFOM
reverses these actions. The data are expressed as nmol Pi generated per slide (mean+ SEM) and are derived from three independent experiments
performed in triplicate (n = 3). Significance level: ***p< 0.001 and **p< 0.01 compared to the treatment with LPA alone.
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bitors towards MGL likely explains the difference in the
inhibition of glycerol production from LPA between the
two inhibitors. The time-dependent generation of Pi and
glycerol from exogenous LPA is presented in Figure 7c. It
appears that Pi generation precedes that of G, a findingsupporting sequential actions of phosphatases and lipases
on the LPA!MAG!G pathway.
Discussion
Functional autoradiography provides a straightforward
approach to study the proximal step of signalling of
Figure 6 Treatment with AlFx
- results in accumulation of
several endogenous LPA species in rat brain sections. The slides
with two horizontal brain sections were treated with AlFx
- (NaF
10 mM+AlCl3 50 μM) for 40 min followed by extraction of LPA
species, as described in Methods. The samples were analyzed with
LC/MS/MS for four endogenous LPA species, 16:0 LPA, 18:0 LPA, 18:1
LPA and 20:4 LPA. The amounts of three of these LPA species are
increased in a statistically significant manner in AlFx
- treated sections
as compared to control sections. The results are expressed as nmol/g
of tissue protein (mean+ SEM) and are derived from three individual
experiments performed in triplicate (n = 3). Significance level:
***p< 0.001 and **p< 0.01 compared to control.
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recently demonstrated that brain sections retain the cap-
acity to generate endocannabinoids during incubations i.
e. evidence of the ability of the brain sections to preserve
sufficient functional enzymatic machinery to generate
endogenous GPCR activating ligands [34]. The lifetime
of the signalling pool of LPA is thought to be controlled
by the equilibrium between synthesizing and degradative
enzymatic activity. In the current study, we have charac-
terized these enzymatic pathways and their role in tonic
LPA1 receptor activity by pharmacologically manipulat-
ing the enzymatic machinery required for LPA degrad-
ation. We observed that in brain sections, the lifetime of
bioactive LPA is controlled by Mg2+-independent, NEM-
insensitive phosphatase activity attributable to LPPs.
Pharmacological inhibition of this LPP activity by AlFx
- ,
propranolol or sodium orthovanadate amplified LPA1
receptor signalling, as revealed using functional auto-
radiography. We provided further evidence to show that
the majority of brain LPA phosphatase activity seems
to be carried out by LPP-like enzymatic activity which
like LPP activity, is sensitive to AlFx
- but appears to be
resistant to the two other LPP inhibitors, vanadate and
propranolol. Finally, we demonstrated that degradation
of exogenous LPA is almost entirely channelled via the
LPA!MAG!G pathway and that MGL accounts
for the majority of oleylglycerol-hydrolyzing activity in
brain tissue.
All the three subtypes of Mg2+-independent/NEM re-
sistant LPPs are expressed in the brain, yet very little isknown about the role of the LPPs as regulators of LPA
receptor signalling in the nervous system. Knockout
studies of all the LPP subtypes have been reported [44-
46]. Study with LPP1 knockout mice indicated that
LPP1 plays a role in regulating the degradation of circu-
lating LPA in vivo but that study failed to disrupt the
LPP1 encoding gene in the brain, obscuring the function
of LPP1 in the nervous system [46]. Knockout of LPP3
turned out to be embryonically lethal [45] whereas
in vitro studies using cell lines lacking LPP3 address in-
volvement of LPP3 in early neural development [47].
The LPPs are likely to be involved in LPA dephosphory-
lation in brain cryosections, as brain sections efficiently
generate Pi from exogenous LPA largely in a NEM re-
sistant and Mg2+-independent way. Propranolol and van-
adate have been demonstrated to inhibit LPPs in various
cell types [20,35,36,48], vanadate also in the rat brain
[49]. Propranolol has been shown to act as a moderately
effective inhibitor of LPPs [20] supporting our finding
where the vanadate-induced response is relatively stron-
ger when compared to the response observed with pro-
pranolol. Since propranolol and vanadate amplified LPA1
receptor signalling only when present in the [35 S]GTPγS
labelling step, these drugs presumably inhibit LPPs in a
reversible manner. In brain sections, LPP activity
appears to locally control the lifetime of the signalling
pool of LPA and LPPs must therefore reside in close
proximity to the LPA1 receptors, as propranolol and
vanadate had no effect on LPA degradation when
assessed at the bulk brain level.
In functional autoradiography, AlFx
- more efficiently
induced the LPA1 receptor-mediated signal as compared
to the signals observed with vanadate or propranolol.
Since AlFx
- is able to induce the LPA1 receptor-mediated
signal when present only in the pre-incubation step, it
appears to inhibit LPPs in an irreversible manner. This
proposal is supported by the finding that the Al3+ chela-
tor DFOM failed to reverse AlFx
- -evoked response, if
added only after pretreatment of brain sections with
AlFx
- (and NaF). AlFx
- is known to mimic the chemical
structure of phosphate and therefore affects the activity
of several phosphoryl transfer enzymes [38]. As a phos-
phate analog, AlFx
- might bind to the Pi recognizing
binding pocket of the LPPs and by this mechanism lead
to irreversible inhibition. All the studied inhibitors
evoked [35 S]GTPγS binding responses that were largely
restricted to the white matter areas of the brain when
compared to grey matter (See Additional file 7: Inhibi-
tor-evoked [35 S]GTPγS binding responses are restricted
to the white matter areas of the brain) reflecting to se-
lectivity towards the myelin-enriched LPA1 receptors.
This also provides evidence to show, that though AlFx
- is
known to act as a general activator of heterotrimeric G
proteins, it seems not to induce global binding response
Figure 7 Rat cerebellar membranes principally metabolize LPA
via the LPA!MAG!G pathway. (a) Rat cerebellar membranes
(1 μg/well) were incubated in the absence (basal) or presence of
LPA, glycerol 3-phosphate (GP), or the phosphatase-resistant LPA
analog (2 S)-OMPT (10 μM final concentration each). Pi generation
was kinetically monitored for 90 min using a fluorescent assay as
described in Methods. Rat cerebellar membranes generate Pi from
exogenous LPA but not from exogenous GP or (2 S)-OMPT. The data
are expressed as nmol of Pi generated per mg of protein during the
90 min incubation (mean+ SEM, n = 4 for basal and LPA, n = 3 for GP
and (2 S)-OMPT). Significance level: ***p< 0.001 compared to basal.
(b) Rat cerebellar membranes were pretreated for 30 min with
DMSO or the broadly-acting serine hydrolase inhibitor MAFP (1 μM)
or the MGL-specific inhibitor JZL184 (100 μM). This was followed by
90 min incubation in the absence (basal) or presence of LPA (10 μM
final concentration). Glycerol generation was kinetically monitored
for 90 min using a fluorescent assay as described in Methods. Rat
cerebellar membranes readily generate glycerol from exogenous
LPA; this response is largely blocked by MAFP and partially so by
JZL184. The data are expressed as nmol of glycerol generated per
mg of protein during the 90 min incubation (mean+ SEM, n = 4).
Significance level: ***p< 0.001 compared to either basal or particular
treatment. (c) Simultaneous kinetic monitoring of Pi and glycerol
generation from exogenous LPA by rat cerebellar membranes
during 90 min incubation. Note that Pi generation precedes and
exceeds that of glycerol during the early time-points (10–30 min)
suggesting temporal first phosphatase (LPA! MAG) then lipase
(MAG! G) action. The data are expressed as nmol of Pi or glycerol
generated per mg of protein and are means of duplicate wells from
one representative experiment.
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as a general G protein activator in functional autoradiog-
raphy. It is notable that in contrast to propranolol and
vanadate, when present in the latter step together with
exogenous LPA, AlFx
- totally prevented the degradation
of LPA at the bulk brain level, suggesting that in
addition to irreversibly inhibiting LPPs, AlFx
- can inhibit
other LPP-like phosphatases in a reversible manner.
Based on the present findings, the major portion of
brain LPA phosphatase activity appears to be attributable
to the LPP-like phosphatases which in a similar manneras LPPs, are sensitive to AlFx
- but resistant to the LPP
inhibitors, vanadate and propranolol.
Since there was no Pi generation from exogenous gly-
cerol 3-phosphate, it seems that LPA is predominantly
degraded by the LPA!MAG!G pathway in our
experimental setting whereas the LPA!GP!G pathway
plays a minor role. According to our findings, both phos-
phohydrolases (LPPs/LPP-like) and MGL and related
hydrolases (ABHD6/ABHD12) seem to be active. The Pi-
and glycerol -generating enzymatic routes involved in LPA
degradation are summarized in Additional file 8: Sum-
mary of enzymatic routes generating Pi and glycerol. Pre-
viously, NEM-insensitive LPA phosphohydrolase activity
was studied in the nuclear fraction isolated from rabbit
cerebral cortex [50]. This activity was found to be present
also in the microsomal fraction. In the nuclear fraction,
phosphohydrolase activity was found to be sensitive to
NaF (50 mM) but virtually insensitive to propranolol
(0.5 mM). Dephosphorylation by phosphohydrolases was
found to be more active route for LPA degradation when
compared to deacylation by lysophospholipases. It was
also indicated that followed by dephosphorylation of
LPA, monoacyl product is rapidly converted to glycerol
by monoglyceride lipase. These findings support our
present findings concerning active pathways involved in
LPA degradation in brain as well as about the existence
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phohydrolase activity.
The LPP-like phosphatases remain to be characterized
in future experiments. One interesting group of brain-
specific membrane proteins are plasticity related genes
(PRGs) that have recently been identified and were origin-
ally proposed to act as LPA phosphatases [51]. Among
the family of PRGs, PRG-1 shares close homology to the
LPPs, having three conserved integral domains facing the
extracellular side of the plasma membrane, the feature
that enables LPPs to dephosphorylate their lipid sub-
strates. However, the catalytic residues responsible for
LPP activity are not fully conserved in PRGs [51] suggest-
ing that PRGs might not act as LPA phosphatases. In-
stead, PGR-1 was recently demonstrated to act at the
postsynaptic side of the excitatory glutamatergic synapse
where it could mediate the uptake of bioactive lipids [52].
PRG-1 was found to effectively control the levels of LPA
in the synapse though its mechanism of action seems to
be more transporter-like than dephosphorylating. The
transporter mechanism is not expected to be active in our
experimental setting and therefore we hypothesize that
PRGs are not controlling LPA levels in our model.
Conclusions
We demonstrate that the lifetime of bioactive LPA is
controlled by LPPs in rat brain cryosections and that
pharmacological inhibition of this LPP activity results in
amplification of basal and LPA-stimulated LPA1 receptor
activity. We conclude that LPP acts locally to control
the lifetime of the signalling pool of LPA in the vicinity
of LPA1 receptors whereas the majority of brain LPA
phosphatase activity is attributable to additional LPP-like
enzymatic activity. Functional autoradiography repre-
sents a valuable tool for studies into LPA degradation by
LPPs and LPP-like enzymatic activity. Compounds
affecting LPA degradation could prove to be attractive
targets for drug development, since altered LPA levels
are associated with common human diseases, e.g. several
forms of cancer. The approach described in this paper
may also prove useful for further studies elucidating
enzymatic pathways regulating the lifetime of still
uncharacterized endogenous signalling lipids.
Methods
Chemicals
Propranolol was purchased from Biomol (Plymouth
Meeting, PA, USA). AlCl3 and NaF were from Merck
(Darmstat, Germany). 1-oleoyl-2-methyl-sn-glycero-3-
phosphothionate ((2S)-OMPT), 1-palmitoyl-2-hydroxy-
sn-glycero-3-phosphate (16:0 LPA), 1-heptadecanoyl-2-
hydroxy-sn-glycero-3-phosphate (17:0 LPA), 1-stearoyl-2-
hydroxy-sn-glycero-3-phosphate (18:0 LPA), 1-arachidonoyl-
2-hydroxy-sn-glycero-3-phosphate (20:4 LPA) were fromAvanti Polar Lipids (Alabaster, AL, USA). 1-oleyl-2-
hydroxy-sn-glycero-3-phosphate (18:1 LPA), sodium ortho-
vanadate (Na3VO4), nadolol, bovine serum albumin (BSA,
fatty acid free), dithiothreitol (DTT), 8-cyclopentyl-1,3-
dipropylxanthine (DPCPX), guanosine diphosphate (GDP),
3-(4-[4-([1-(2 chlorophenyl)ethoxy] carbonyl amino)-3-
methyl-5-isoxazolyl]benzylsulfanyl) propanoic acid (Ki16425),
GTPγS, N-ethylmaleimide (NEM), glycerol 3-phosphate,
and deferoxamine mesylate (DFOM) were from Sigma
(St Louis, MO, USA). Methylarachidonoylfluorophospho-
nate (MAFP) and compound JZL184 were from Cayman
Chemical (Ann Arbor, MI, USA). [35 S]GTPγS (initial spe-
cific activity 1250 Ci/mmol) was purchased from NEN
Life Science Products Inc. (Boston, MA, USA). All other
chemicals were of the finest purity available.
Animals
Experiments were performed using 4-week old male
Wistar rats obtained from the National Laboratory
Animal Centre, University of Eastern Finland, Kuopio,
Finland. Approval for the harvesting of animal tissue
was applied, registered and obtained from the local wel-
fare officer of the University of Eastern Finland. The
experiments did not involve any in vivo treatment. The
animals were housed in groups of five to ten individuals
per cage under standard laboratory conditions (12–12 h
light–dark cycle, food and water ad libitum, 60% rela-
tive humidity). The rats were decapitated 8–9 h after
lights on, and within the next 5 min, the whole brain
was dissected out, dipped briefly in isopentane (chilled
on dry ice) and stored at −80 °C. Horizontal, coronal or
sagittal brain sections (20 μm thick) were cut at −19 °C
to −21 °C using a Leica cryostat, thaw-mounted onto
SuperfrostWPlus slides (Menzel-Gläser, Germany), dried
for 1–4 h at room temperature under a constant stream
of air and stored thereafter at −80 °C.
[35 S]GTPγS autoradiography
[35 S]GTPγS autoradiography was performed as previ-
ously described [26,28,34]. Briefly, the brain sections
were processed in three sequential steps consisting of
pre-incubation for 20/40 min (step 1), GDP-loading for
50/60 min (step 2), and [35 S]GTPγS labelling for 90 min
(step 3). For some treatments, a brief additional incuba-
tion (10 min) was performed prior to step 1, as detailed
in Results. All the steps were performed at 20 °C using
Tris-based buffer (50 mM Tris–HCl, pH 7.4, 1 mM
EDTA, 100 mM NaCl, 5 mM MgCl2). Steps 2 and 3
included 1 μM DPCPX (to block the tonic adenosine A1
receptor signal) and 2 mM GDP and step 3 additionally
included 1 mM DTT and 40–250 pM [35 S]GTPγS. Che-
micals being investigated (LPA species used was 18:1
LPA) and 0.1% BSA (fatty acid free) were included in the
assay during steps 1,2 or 3 as described in Results. In
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in the presence of 10 μM GTPγS to determine non-
specific binding. After the 90 min autoradiography step,
the slides were rinsed twice (5 min each time) in ice-
cold washing buffer (50 mM Tris–HCl, pH 7.4 and
5 mM MgCl2), dipped for 30 s in ice-cold deionized
water, and air-dried. The slides were arranged into a cas-
sette together with [14 C] standard (Amersham, Little
Chalfont, Bucks, UK) and exposed against a radiosensi-
tive film (BioMax MR™, Kodak Scientific Imaging Film)
for 2–5 days. After exposure, the films were developed
for 3–4 min at 4 °C with Kodak D-19 developer.
[35 S]GTPγS membrane binding assay
A previously described method was utilized for prepar-
ation of membranes [39]. Briefly, eight cerebella were
homogenized in nine volumes of ice-cold 0.32 M su-
crose. The homogenate was centrifuged at 1000 × g for
10 min at 4 °C and the resulting supernatant was centri-
fuged at 100 000 × g for 30 min at 4 °C. The high speed
centrifugation was repeated twice, resuspending the pel-
let in ice-cold deionised water. After the final centrifuga-
tion, the membranes were suspended in Tris–HCl
(50 mM, pH 7.4) supplemented with EDTA (1 mM) and
stored thereafter at −80 °C.
The [35 S]GTPγS membrane binding assay was per-
formed as previously described [28,34], with minor mod-
ifications. Briefly, the final incubation volume (400 μl)
contained 5 μg membrane protein in the incubation buf-
fer (50 mM Tris–HCl, pH 7.4, 1 mM EDTA, 100 mM
NaCl, 5 mM MgCl2, 10 μM GDP, 1 mM DTT, 0.5%
BSA, and ~ 150 pM [35 S]GTPγS) plus the chemicals of
interest. The incubation buffer was supplemented with
1 μM DPCPX to suppress basal [35 S]GTPγS binding due
to endogenous adenosine. The membranes were pre-
incubated for 30 min prior to conducting the [35 S]
GTPγS binding step. The incubations were stopped after
90 min by the addition of 4 ml ice-cold washing buffer
(50 mM Tris–HCl, pH 7.4 and 5 mM MgCl2), followed
by filtration through glass fibre filters (Whatman GF/B)
and by two additional washes with the buffer. The filters
were transferred into scintillation vials along with
HiSafe3 scintillation liquid (Wallac, Turku, Finland).
After vertical shaking for 15 min to extract radioactivity
trapped in filters, the tubes were counted the next day
with Wallac LKB 1213 Rackbeta, Wallac, Turku, Finland.
Determination of Pi and glycerol
To estimate LPA-degrading phosphatase activity under
the assay conditions mimicking functional autoradiog-
raphy, triplicate slides with two or three horizontal brain
sections underwent the autoradiography mimicking
protocol (except that DPCPX, GDP and radioligand were
omitted). The experiments with Na3VO4, propranolol,and nadolol (as a negative control for propranolol) were
performed with and without NEM pretreatment. The
protocol consisted of 10 min pre-incubation in the assay
buffer, 30 min incubation in the assay buffer with or
without 5 mM NEM, then a washing step with assay
buffer, and finally 90 min incubation in the presence of
chemicals in interest as well as 0.1% BSA and 1 mM
DTT. In NEM-treated sections, Mg2+ was omitted from
the assay buffer. In experiments with NaF and AlFx
- , the
protocol consisted of two sequential 40 min incubations
(steps 1 and 2) and finally 90 min incubation (step 3) in
the presence of the chemicals of interest as well as 0.1%
BSA and 1 mM DTT. LPA species used was 18:1 LPA.
In all experiments, after the final 90 min incubation step,
the postincubation buffer was collected quantitatively
and the Pi content was determined in duplicate using
the Fiske-Subbarow method, as described in Esmann
(1988) [53] after TCA-precipitation of BSA which inter-
fered with the Pi determinations. Absorbances (λ 700 nm)
were read with a Tecan Spectrafluor microplate reader.
To clarify the enzymatic routes responsible for LPA
degradation in our experimental setting, Pi formation
was determined using enzyme-coupling fluorescent
method [54]. The glycerol content was determined using
a coupled enzyme reaction (Free Glycerol Reagent,
Sigma, Cat.# F6428) with the exception that H2O2 pro-
duction was coupled to peroxidase-dependent formation
of the fluorescent dye resorufin. Briefly, rat cerebellar
membranes (1 μg/well of 96-well plate), prepared as
described in [39], were pretreated with the serine hydro-
lase inhibitors MAFP (1 μM) or JZL184 (100 μM) for
30 min and then incubated with or without 18:1 LPA,
GP, or (2 S)-OMPT (10 μM final concentration). The
fluorescence (λex 530 nm, λem 590 nm) was monitored
kinetically for 90 min at 10 min intervals using Tecan
Infinite M200 fluorometer.
Extraction of LPA for mass spectrometric determination
Slides with two horizontal brain sections were incubated
for 40 min in the presence of AlFx
- (NaF 10 mM+AlCl3
50 μM) mimicking the [35 S]GTPγS autoradiography.
The control slides were incubated similarly in the assay
buffer. After 40 min incubation, slides were rinsed twice
(2 min each time) in ice-cold washing buffer, dipped
for 30s in ice-cold deionized water and air-dried. The
modified extraction method of Bligh and Dyer [55]
was applied for the isolation of LPA from the tissue
matrix. One sample consisted of pooled tissue obtained
from four slides. The brain tissue was scraped manually
from the slides with a spatula using the mixture of
50 mM Tris–HCl, pH 7.40 and methanol with a ratio of
1:4 (v/v); this mixture also included an internal standard
(17:0 LPA) used in the quantification. The tissue was
transferred to a screw-capped PyrexW borosilicate glass
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methanol (1:4, v/v) was added to the test tube to bring
the volume up to 200 μl. Chloroform was added to yield
a water/methanol/chloroform ratio of 1:4:2 (v/v/v) and
the samples were shaken for 1 h with a vertical shaker
(Heidolph Multi Reax, Heidolph Instruments GmbH &
Co, Schwabach, Germany). To achieve the phase separ-
ation, 80 μl of chloroform and 80 μl of water were
added. After vortexing for 1 min, the samples were cen-
trifuged at 1800 x g for 15 min at room temperature.
The upper aqueous layer was transferred to an HPLC
sample vial.
Liquid chromatography/tandem mass spectrometry
(LC/MS/MS)
The method for LC/MS/MS determination of LPAs with
varying acyl chains has been previously described [9].
The HPLC system comprised of an Agilent 1200 Series
Rapid Resolution LC System (Agilent Technologies,
Waldbronn, Germany) consisting of a solvent micro vac-
uum degasser, a binary pump, a thermostatted column
compartment SL, and an autosampler SL. Ten microliter
of sample solution were injected onto a reversed phase
HPLC column (XBridge™ C8 2.1x50 mm, 2.5 μm)
(Waters, Ireland) using gradient elution with 50 μM
ammonium acetate + 1% triethylamine (TEA) (A) and
1% TEA in 90% methanol (B) as follows: 0–6.0 min 20%
B! 90% B, 6.0-10.0 min 90% B, 10.0-10.1 min 90%
B! 20% B, 10.0-15.0 min 20% B. The flow rate
was 0.3 ml/min, column temperature was maintained at
40 °C and the autosampler tray temperature was set to
10 °C.
The mass spectrometric analysis was carried out with
an Agilent 6410 Triple Quadrupole LC/MS equipped
with an electrospray ionization source (Agilent Tech-
nologies, Palo Alto, CA, USA). The following ionization
conditions were used: ESI negative ion mode, drying gas
(nitrogen) temperature 300 °C, drying gas flow rate 8 l/
min, nebulizer pressure 40 psi and capillary voltage
4000 V. Analyte detection was performed using multiple
reaction monitoring (MRM) with the following transi-
tions: m/z 409! 153 for 16:0 LPA, m/z 437! 153 for
18:0 LPA, m/z 435! 153 for 18:1 LPA, m/z 457! 153
for 20:4 LPA, and m/z 423! 153 for 17:0 LPA. The
fragmentor voltage was 160 V and collision energy 20 V
except 23 V for 17:0 LPA. Data were acquired by Agilent
MassHunter Workstation Acquisition software (Agilent
Technologies, Data Acquisition for Triple Quad., version
B.01.03).
Data analysis
Autoradiography films were digitized using a HP scan-
jet 7400c scanner. For the quantitative data, optical
densities on the autoradiograms were measured usingImageJ, a freely available java-based image analysis soft-
ware system developed in the National Institutes of
Health, USA (http://rsb.info.nih.gov/ij/). Optical dens-
ities were converted to nCi/g using nonlinear transform-
ation built by the greyscale values of [14 C] standards. In
LC/MS/MS experiments, an internal standard (17:0
LPA) was used for quantification, and peak area ratios of
the analyte to the IS were calculated as a function of the
concentration ratios of the analyte to the internal stand-
ard using Agilent MassHunter software (Quantitative
Analysis Version B.01.03). The protein content of brain
sections was determined by the Pierce BCA Protein
Assay Kit with BSA as the standard. The statistical dif-
ferences were determined either using one-way ANOVA
with Tukey’s multiple comparison post hoc test or t test
(LC/MS/MS experiments) with ***p< 0.001, **p< 0.01,
or *p< 0.05 considered as statistically significant. All
statistical data analyses were conducted using GraphPad
Prism for Windows.
Additional files
Additional file 1: The maximal effective concentrations for Na3VO4
and propranolol. (Autoradiography image)
Additional file 2: Propranolol, but not nadolol, induces LPA
mimicking binding response. (Autoradiography image)
Additional file 3: Propranolol and vanadate do not activate LPA1
receptors. (Graph)
Additional file 4: Comparison of the [35 S]GTPγS binding responses
between LPA and (2 S)-OMPT. (Autoradiography image)
Additional file 5: Autotaxin is not responsible for tonic LPA1
activity. (Autoradiography image)
Additional file 6: Phosphate generation from exogenous LPA, PA,
and S1P. (Graph)
Additional file 7: Inhibitor-evoked [35 S]GTPγS binding responses
are restricted to the white matter areas of the brain. (Graph)




- : Aluminium fluoride; BSA: Bovine serum
albumin; DFOM: Deferoxamine mesylate; GP: Glycerol phosphate; GPCR: G
protein-coupled receptor; LC/MS/MS: Liquid chromatography/tandem mass
spectrometry; LPA: Lysophosphatidic acid; LPP: Lipid phosphate phosphatase;
MAG: Monoacylglycerol; MGL: Monoglyceride lipase; NaF: Sodium fluoride;
Na3VO4: Sodium orthovanadate; NEM: N-ethylmaleimide; PA: Phosphatidic
acid; Pi: Inorganic phosphate; S1P: Sphingosine 1-phosphate.
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